This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 14 of 254 for:    macular degeneration | Recruiting, Not yet recruiting, Available Studies

Microperimetry and Eye Progressing From Stage 3 to Stage 4 Age-related Macular Degeneration (AMD) (PREVISION)

This study is currently recruiting participants.
See Contacts and Locations
Verified October 2016 by Hospices Civils de Lyon
Sponsor:
Collaborator:
Novartis
Information provided by (Responsible Party):
Hospices Civils de Lyon
ClinicalTrials.gov Identifier:
NCT02395757
First received: February 20, 2015
Last updated: October 4, 2016
Last verified: October 2016
  Purpose

Age-related macular degeneration (AMD) is an acquired retinal pathology affecting the central region of the retina responsible for discrimination between high spatial frequencies (reading), colour vision and the central visual field. The loss of visual acuity which occurs with the onset of AMD significantly affects patients' quality of life. In developed countries, AMD is the leading cause of vision impairment for people aged over 50 years. Its prevalence in Europe in people aged over 65 years is 3.3%. In France, around 2 million people suffer from this disease.

In the first stage of the disease it is known as age-related maculopathy (ARM). This early form of the disease can develop into intermediate AMD (stage 3 of the AREDS classification) and then advanced AMD (stage 4 AREDS), which can be atrophic or exudative. In cases of exudative AMD, the intravitreal administration of anti-VEGF drugs can limit the disease's progression.

It is therefore vital to adopt a strategy to assess the stage of the disease and provide the appropriate care management at the earliest possible stage. This is even more important for patients with advanced AMD in one eye and intermediate AMD in the fellow eye, as the risk of the fellow eye progressing to the advanced stage within 5 years is between 35% and 53%.

Microperimetry is a promising new diagnostic method which combines measurements of light sensitivity, loss of fixation and the anatomy of the retina. It offers a new approach to the functional assessment of retinal damage in patients with AMD, as it precisely correlates anatomical and functional modifications by measuring the loss of sensitivity and macular fixation. It has been shown that the more advanced the patient's AMD is, the further the parameters measured by microperimetry are from the norm.

The investigators want to assess the MAIA™ as a means of screening for AMD progression in patients with a high risk of progressing to a more advanced stage (patients presenting one eye with advanced AMD and a fellow eye with stage 3 AMD according to the AREDS classification). The research hypothesis for our proposed study is that the parameters measured using microperimetry will already show abnormal results in the study eye prior to progressing to a more advanced stage of the disease. The use of these microperimetric parameters as predictor of progression would therefore make it possible to screen eyes likely to develop from intermediate to advanced AMD at an earlier stage, and subsequently provide patients who need it with earlier follow-up, preventive treatment or adapted, personalized rehabilitation as appropriate.


Condition Intervention
Stage 3 Age Related Macular Degeneration (AREDS Classification) Device: MAIA™ (Centrevue, Padova, Italy; distributed in France by EDC Lamy, Carvin, France)

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Assessment Using Microperimetry of the Risk of a Fellow Eye Progressing From Stage 3 to Stage 4 (AREDS Classification) Age-related Macular Degeneration (AMD)

Resource links provided by NLM:


Further study details as provided by Hospices Civils de Lyon:

Primary Outcome Measures:
  • The sensitivity of the microperimetric parameter(s) and combination(s) of parameters according to patient status at final assessment. [ Time Frame: 24 months ]
    The sensitivity of the microperimetry diagnostic tool will be measured by the ratio between the number of patients presenting both positive microperimetric parameters and advanced AMD (stage 4); and the total number of patients with advanced AMD diagnosed at final assessment.


Secondary Outcome Measures:
  • The specificity of the microperimetric parameter or combination of parameters with the highest level of sensitivity [ Time Frame: 24 months after inclusion ]
    The specificity of the microperimetry diagnostic tool will be measured by the ratio between the number of patients presenting both negative microperimetric parameters and no advanced AMD (stage 4); and the total number of patients with no advanced AMD diagnosed at final assessment.

  • The positive predictive value of the microperimetric parameter or combination of parameters with the highest level of sensitivity [ Time Frame: 24 months after inclusion ]
    The positive predictive value of the microperimetry diagnostic tool will be measured by the ratio between the number of patients presenting both positive microperimetric parameters and advanced AMD (stage 4); and the total number of patients with positive microperimetric parameters.

  • The negative predictive value of the microperimetric parameter or combination of parameters with the highest level of sensitivity [ Time Frame: 24 months after inclusion ]
    The negative predictive value of the microperimetry diagnostic tool will be measured by the ratio between the number of patients presenting both negative microperimetric parameters and no advanced AMD (stage 4); and the total number of patients with negative microperimetric parameters.

  • The sensitivity of the microperimetric parameters associated with the parameters from other ophthalmological examinations. [ Time Frame: 24 months after inclusion ]
    The parameters of other ophthalmological examinations considered will be as follows: best corrected visual acuity measured according to ETDRS (number of letters) and Snellen scales; foveolar thickness, central 1-mm thickness, external limiting membrane (ELM) integrity, and ellipsoidal line integrity measured using SD-OCT (spectral domain optical coherence tomography). The sensitivity will be measured by the ratio between the number of patients presenting both positive parameters and advanced AMD (stage 4); and the total number of patients with advanced AMD diagnosed at final assessment.

  • The specificity of the microperimetric parameters associated with the parameters from other ophthalmological examinations. [ Time Frame: 24 months after inclusion ]
    The parameters of other ophthalmological examinations considered will be as follows: best corrected visual acuity measured according to ETDRS (number of letters) and Snellen scales; foveolar thickness, central 1-mm thickness, external limiting membrane (ELM) integrity, and ellipsoidal line integrity measured using SD-OCT. The specificity will be measured by the ratio between the number of patients presenting both negative parameters and no advanced AMD (stage 4); and the total number of patients with no advanced AMD diagnosed at final assessment.

  • The sensitivity of the microperimetric parameters or combinations of parameters for the sub-group of eyes presenting reticular pseudodrusen at inclusion. [ Time Frame: 24 months after inclusion ]
    The sensitivity will be measured by the ratio between the number of patients presenting both positive parameters and advanced AMD (stage 4); and the total number of patients with advanced AMD diagnosed at final assessment.

  • The specificity of the microperimetric parameters or combinations of parameters for the sub-group of eyes presenting reticular pseudodrusen at inclusion. [ Time Frame: 24 months after inclusion ]
    The specificity will be measured by the ratio between the number of patients presenting both negative parameters and no advanced AMD (stage 4); and the total number of patients with no advanced AMD diagnosed at final assessment.


Estimated Enrollment: 300
Study Start Date: September 2015
Estimated Study Completion Date: September 2018
Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Microperimetry
Microperimetry exam performed in addition to the usual ophthalmological examinations for monitoring AMD.
Device: MAIA™ (Centrevue, Padova, Italy; distributed in France by EDC Lamy, Carvin, France)

  Eligibility

Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient aged 50 years or over;
  • Patient who has given their free, informed, signed consent;
  • Patient with a French social security number or equivalent cover;
  • Patient presenting one eye with stage 4 AMD (according to the AREDS classification), and drusen in the fellow eye (study eye) with at least one drusen with a diameter of over 125 microns and/or extra- foveal atrophy (stage 3 AREDS);
  • Patient who is willing and able to attend all the clinical appointments required for the study and complete all the related procedures.

Exclusion Criteria:

  • Patient aged under 50 years;
  • Patient who refuses to take part in the study;
  • Woman who is pregnant or breastfeeding;
  • Protected adult as set out in French law (French Public Health Law);
  • Patient presenting a study eye with stage 1, 2 or 4 AMD (AREDS classification);
  • Patient presenting another maculopathy in the study eye;
  • Area alteration (cornea, lens, vitreous humour) which makes it impossible to carry out and interpret the microperimetry correctly;
  • Patient due to undergo cataract surgery in the study eye during the 2-year study period;
  • Patients who cannot be followed up for the full 2 years;
  • Patients participating simultaneously in other studies which may interfere with the study results (in either eye).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02395757

Contacts
Contact: Laurent KODJIKIAN, Professor +33 4.26.10.93.21 ext 94.29 laurent.kodjikian@chu-lyon.fr
Contact: Soumia BAYARASSOU +33 4.72.11.51.69 soumia.bayarassou01@chu-lyon.fr

Locations
France
Hospice Civils de Lyon Recruiting
Lyon, France, 69000
Contact: Laurent KODJIKIAN, MD    4 26 10 93 21 ext 0033    laurent.kodjikian@chu-lyon.fr   
Sponsors and Collaborators
Hospices Civils de Lyon
Novartis
  More Information

Responsible Party: Hospices Civils de Lyon
ClinicalTrials.gov Identifier: NCT02395757     History of Changes
Other Study ID Numbers: 2014.862
Study First Received: February 20, 2015
Last Updated: October 4, 2016

Keywords provided by Hospices Civils de Lyon:
Age Related Macular Degeneration (AMD)
Microperimetry
Diagnostic

Additional relevant MeSH terms:
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases

ClinicalTrials.gov processed this record on June 26, 2017